Trial comparisons

curl "https://conductscience.org/api/comparisons/v1?page=239"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=239

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT05513053-8d124c6a",
        "title": "Cohort 1: Participants Aged 9 to 17 Years vs Cohort 2: Participants Aged 18 to 49 Years: Number of Participants With Medically Attended Adverse Events (MAAEs)",
        "summary": "27 of 641 against 35 of 658; risk difference -1.1 points, 95% interval -3.5 to 1.3; NCT05513053, Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.",
        "record": "/library/comparisons/NCT05513053-8d124c6a",
        "nct_id": "NCT05513053",
        "kind": "outcome",
        "participants": 1299,
        "risk_difference": {
          "value": -0.01106980449430743,
          "lower": -0.03483570959191211,
          "upper": 0.012534972395294552
        },
        "group_1": "27 of 641",
        "group_2": "35 of 658",
        "difference": "-1.1 points",
        "interval": "-3.5 to 1.3",
        "trial_title": "Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age."
      },
      {
        "id": "NCT05513053-sae",
        "title": "Cohort 1: Participants Aged 9 to 17 Years vs Cohort 2: Participants Aged 18 to 49 Years: serious adverse events",
        "summary": "3 of 641 against 7 of 658; risk difference -0.6 points, 95% interval -1.8 to 0.5; NCT05513053, Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age.",
        "record": "/library/comparisons/NCT05513053-sae",
        "nct_id": "NCT05513053",
        "kind": "serious-adverse-events",
        "participants": 1299,
        "risk_difference": {
          "value": -0.005958110664852126,
          "lower": -0.017533840869292397,
          "upper": 0.004567126080172845
        },
        "group_1": "3 of 641",
        "group_2": "7 of 658",
        "difference": "-0.6 points",
        "interval": "-1.8 to 0.5",
        "trial_title": "Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) in Participants 9 Through 49 Years of Age."
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=240",
  "request_id": "9LPcez_ty0vvZRff"
}